Handelsavisen
prelaunch
17
1707.TW TWSE Food Processing

Grape King Bio Ltd

$100,50
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
14,9B TWD
P/E
EV / Rev
Div yield
5,33 %
Op margin
20,9 %
ROE
11,8 %
Net margin
11,9 %
Debt / equity
0,02
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Grape King Bio Ltd is a food processing company that produces and sells food products, primarily generating revenue through the sale of its processed food items.

Business. Grape King Bio Ltd (1707.TW) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Beverages
IndustryFood Processing
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target138,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
138,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
11,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1707.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1707.TW. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Grape King Bio Ltd (1707.TW) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Beverages
    IndustryFood Processing
    AI synthesis
    GENERATED

    Grape King Bio Ltd maintains a strong liquidity position, with a current ratio of 1.65 and cash and equivalents amounting to TWD 2,334,573,000. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet short-term obligations. The debt-to-equity ratio is low at 0.02, suggesting minimal leverage and a conservative capital structure.

    In terms of profitability, Grape King Bio Ltd demonstrates a return on equity (ROE) of 11.78% and a return on assets (ROA) of 7.74%, both of which are strong indicators of efficient asset utilization and profitability. The company's operating margin is 20.9%, and its net profit margin is 11.9%, which are favorable compared to industry benchmarks.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification mentioned. This concentration may pose a risk if the segment faces any downturns.

    Grape King Bio Ltd has shown consistent revenue growth, with a revenue of TWD 10,251,607,000 in the latest reporting period. The company's outlook for the current fiscal year is positive, with analysts providing a mean price target of TWD 138.00, indicating confidence in its future performance.

    The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The dilution potential is also low, and the company has not issued any new shares recently, maintaining a stable capital structure.

    Recent events, including analyst estimates and price targets, suggest a positive outlook for Grape King Bio Ltd. The company has received a mean recommendation of 2.00, indicating a "Buy" rating from analysts, with one analyst specifically recommending a "Buy".

    Key takeaways
    • Grape King Bio Ltd has a strong liquidity position with a current ratio of 1.65 and significant cash reserves.
    • The company's profitability metrics, including ROE of 11.78% and ROA of 7.74%, are robust and indicate efficient operations.
    • The company's revenue is concentrated in a single business segment, which may pose a risk if that segment faces challenges.
    • Analysts have a positive outlook for Grape King Bio Ltd, with a mean price target of TWD 138.00 and a "Buy" recommendation.
    • The company's low debt-to-equity ratio of 0.02 suggests a conservative capital structure and minimal leverage risk.
    • "margin_outlook_rationale": "The company's operating margin of 20.9% and net profit margin of 11.9% indicate strong profitability, which is expected to be maintained due to efficient cost management.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $100,50
    Market cap
    $14.89B
    Enterprise value
    $12.77B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    5.9x
    P / B
    1.4x
    P / Tangible book
    1.4x
    Tangible book
    $10.34B
    Net cash
    $2.12B
    Current ratio
    1.6
    Debt / equity
    0.0
    ROA
    7.7%
    ROE
    11.8%
    Cash conversion
    179.0%
    CapEx / revenue
    -4.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    9,88
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-20 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate9,88
    Revenueno estimateno estimate11,2B TWD
    Operating incomeno estimateno estimate2,5B TWD
    Full-year consensus mean (period as reported by source) · consensus in TWD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$138,00 · Median $138,00
    Low $138,00High $138,00
    Operating income · consensus2,5B TWD
    EPS surprise
    −17,3 %
    reported vs consensus · miss
    Revenue surprise
    −8,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$138,00
    Mean$138,00
    Median$138,00
    High$138,00
    Spot$100,50
    +37.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin20,9 %Best in class
    Net Margin11,9 %Above P75
    ROE11,8 %Above P75
    Capex / Rev-4,5 %Below median
    D/E0,02Above P75
    Cash Conv1,79Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Grape King Bio Ltd Market data — financials · 2026-05-26
    • Grape King Bio Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1707.TWCanonical
    TWSE · TWD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage